Organigram Reports Health Canada Approval of New Grow Rooms, Increased Yields and Upward Revision to Production Capacity Forecasts | CashCropToday
0 Shares 307 Views

Organigram Reports Health Canada Approval of Phase 2 Expansion

March 6, 2018
307 Views

On March 6, 2018 Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, announced that it had received Health Canada approval for the remaining 13 rooms of its 23 room Phase 2 expansion a week ahead of schedule. The Company expects harvests from the Phase 2 expansion to begin the third week of April.

The Phase 2 expansion will reportedly include significant improvements and efficiencies to the company’s cultivation and processing systems. Planned enhancements will include a fully automated irrigation system, automated potting, a fully automated waste destruction system and automated packaging. Organigram’s approach to production has been trending yields that are in some cases 50% higher than its previous estimates and the company fully anticipates this to continue with enhanced improvements in cultivation and environmental design in Phase 3 and Phase 4 as well as through achievements of economies of scale through optimization of its pre-vegetation and cloning processes.

According to Organigram CEO, Greg Engel, the company is, “seeing some harvest yields that are more than 400 grams per square foot a year and have witnessed the quality, density and size of flowers improve tremendously.” The company now expects that by early 2020 it will be producing over 110,000 kg/year from fully funded operations. Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
269 views
Market Watch
269 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
192 views
Global
192 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
189 views
Manufacturing
189 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: